Small molecule · Inhibitor of hepatitis B virus core protein · developed by Assembly Biosciences
Vebicorvir (VBR) is an oral tablet that inhibits the hepatitis B virus core protein. It is studied in chronic hepatitis B, given as 300 mg once daily.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04820686 | Phase 2 | Chronic Hepatitis B | Terminated | ABUS |
| NCT04781647 | Phase 2 | Chronic Hepatitis B | Terminated | ASMB |
| NCT04637139 | Phase 1 | Chronic Hepatitis B | Completed | ASMB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Hepatitis B
Updated Oct 11, 2026. Something wrong or missing? Report it on the ASMB page.
See ASMB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ASMB catalysts and pipeline →